Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Current Leases (2019 - 2025)

Historic Current Leases for Dexcom (DXCM) over the last 7 years, with Q4 2025 value amounting to $21.6 million.

  • Dexcom's Current Leases fell 400.0% to $21.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $21.6 million, marking a year-over-year decrease of 400.0%. This contributed to the annual value of $21.6 million for FY2025, which is 400.0% down from last year.
  • Dexcom's Current Leases amounted to $21.6 million in Q4 2025, which was down 400.0% from $23.6 million recorded in Q3 2025.
  • In the past 5 years, Dexcom's Current Leases registered a high of $23.6 million during Q3 2025, and its lowest value of $18.2 million during Q1 2021.
  • Over the past 5 years, Dexcom's median Current Leases value was $21.2 million (recorded in 2022), while the average stood at $21.2 million.
  • In the last 5 years, Dexcom's Current Leases surged by 2551.72% in 2021 and then tumbled by 675.68% in 2024.
  • Over the past 5 years, Dexcom's Current Leases (Quarter) stood at $20.5 million in 2021, then changed by 0.0% to $20.5 million in 2022, then grew by 2.93% to $21.1 million in 2023, then increased by 6.64% to $22.5 million in 2024, then dropped by 4.0% to $21.6 million in 2025.
  • Its Current Leases stands at $21.6 million for Q4 2025, versus $23.6 million for Q3 2025 and $23.4 million for Q2 2025.